Penile cancer is a rare, aggressive malignancy, with incidence varying geographically. The primary risk factor is HPV infection. Squamous cell carcinoma represents the most common histological subtype ...

Metastatic clear-cell renal cell carcinoma (mccRCC) remains a major cause of morbidity and mortality among patients with kidney cancer. Over the past two decades, mccRCC treatment has significantly ...

Despite significant progress in the diagnosis and treatment of renal cell carcinoma (RCC), approximately 20% of patients present with metastatic disease, and up to 30% of patients with localized ...

To investigate the risk of upper urinary tract urothelial carcinoma (UTUC) in patients with non-muscle-invasive bladder cancer (NMIBC), in relation to the primary NMIBC tumour risk categories, ...

Perirectal spacers reduce the radiotherapy (RT) dose delivered to the rectum, but their impact on treatment toxicity remains debated. We conducted a systematic review and meta-analysis to synthesise ...

Outcomes of adjuvant (aRT) or salvage radiation therapy (sRT) after radical prostatectomy are under investigation regarding cancer-control outcomes. Relying on the University Cancer Center database ...

(UroToday.com) Dr. Banna Hussain presented important new data from the Michigan Urological Surgery Improvement Collaborative (MUSIC), shedding light on the real-world implementation and outcomes of ...

(UroToday.com) The 2025 AUA annual meeting featured the IBCG Bladder Cancer Forum evaluating common problems and controversies in bladder cancer, moderated by Dr. Peter Black, with a debate between ...

(UroToday.com) The American Urological Association's 2025 Annual Meeting, in Las Vegas, Nevada, was host to the Plenary Session on Saturday. Dr. Samir Taneja gave the State-of-the-Art Lecture titled: ...

Impact of Previous Pelvic Radiotherapy on PSMA PET Outcomes in Patients Experiencing Biochemical Recurrence after Radical Prostatectomy. Implications for Optimal Timing of Restaging Antony Pellegrino ...

Antibody-drug conjugates (ADCs) targeting HER2, NECTIN4, and TROP-2 have emerged as effective therapeutic options for patients with muscle-invasive bladder cancer (MIBC). A recent study by Dernbach et ...